Medivation Announces Participation at Upcoming Investor Conferences
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 03/02/12 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conferences in March:
Patrick Machado, chief business and financial officer, will present at Cowen and Company's 32nd Annual Healthcare Conference on Tuesday, March 6 at 8:00a.m. Eastern Time.
David Hung, M.D., president and chief executive officer, will present at Barclays Capital Global Healthcare Conference on Tuesday, March 13 at 8:30a.m. Eastern Time.
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has its investigational drug MDV3100 in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at .
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.03.2012 - 21:30 Uhr
Sprache: Deutsch
News-ID 121247
Anzahl Zeichen: 0
contact information:
Town:
SAN FRANCISCO, CA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medivation Announces Participation at Upcoming Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Medivation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
